Ultragenyx Pharmaceutical Inc.
RARE
Positions held
Your positionsRARE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Ultragenyx Pharmaceutical Inc. is positioned in the biotechnology industry, focusing on innovative therapies for rare diseases, which can lead to significant market opportunities as the demand for specialized treatments
- In the latest quarter, Ultragenyx reported a revenue increase of 57% compared to the prior quarter, reaching $214 million.
- The gross margin improved to 84.1%, up from 78% in the previous quarter.
- Despite growth in revenue, Ultragenyx has a concerning profit margin of -81.7%, indicating ongoing financial challenges.
- The operating margin remains negative at -35% for the latest quarter, reflecting persistent operational inefficiencies.
- The company has a negative free cash flow of $221.79 million, which raises concerns about its financial sustainability.
Fundamentals
| Market cap | $1.51B | Enterprise value | $2.42B | Trailing P/E | — | Forward P/E | 22.59 |
| PEG | — | Price / book | -5.17 | Beta | 0.35 | Dividend yield | 0.00% |
| Revenue growth | 28.1% | Earnings growth | — | Gross margin | -20.8% | Operating margin | -35.0% |
| Profit margin | -81.7% | ROE | — | ROA | -24.2% | Debt / equity | — |
| Current ratio | 1.73 | Free cash flow | -$221.79M | Analyst recommendation | buy | Mean target | $26.79 |
| 52w high | $39.89 | 52w low | $12.73 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $673M | $560M | $434M | $363M | — |
| Op margin | -79.5% | -95.7% | -131.1% | -178.6% | — |
| Net income | -$575M | -$569M | -$607M | -$707M | — |
| Gross margin | 83.8% | 86.3% | 89.6% | 92.2% | — |
| Gross profit | $564M | $483M | $389M | $335M | — |
| Operating income | -$535M | -$536M | -$569M | -$649M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-08 · Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?
2026-10-07 · Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
2026-10-07 · Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
2026-10-07 · Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
2026-10-07 · Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
2026-10-07 · MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high
2026-10-07 · Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?
2026-10-05 · Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
2026-09-22 · RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
2026-09-22 · FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Price (daily)
Full chart · RSI · MACD · patterns